TD-6450 MAD Study in HCV Infected Subjects

NCT02116543 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
HCV

Interventions

DRUG: TD-6450
DRUG: Placebo

Sponsor

Theravance Biopharma